IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Learn more about:
Related Clinical Trial
Data Analysis of Protocol 04-N-0188: Neurophysiological Markers in Patients With Craniofacial Dystonia and Their Relatives Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm Testing the Effect of Zinc Supplementation to Improve the Treatment Effect of Botulinum Toxin for Oculofacial Spasm Mexiletine for the Treatment of Focal Dystonia A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm An RCT of a Patient-initiated Treatment Service for BEB and HFS Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm Analysis of Gait Before and After Botulinum Toxin Treatment in Patients With Focal Dystonia Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm Photic Blink Reflex in People With Blepharospasm and Increased Blinking IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm Blepharospasm Short Interval Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm Brain Changes in Blepharospasm Blepharospasm Patient Survey for Patients With Blepharospasm A Mechanical Device for Blepharospasm Blepharospasm Tools Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States

Brief Title

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Official Title

Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With an Open-label Extension Period to Investigate the Efficacy and Safety of incobotulinumtoxinA (Xeomin) in the Treatment of Blepharospasm

Brief Summary

      Patients received one injection with incobotulinumtoxinA (Xeomin) or placebo at baseline.
      Thereafter, all patients who entered the Open-Label Extension Period (OLEX) received up to
      five injection sessions of incobotulinumtoxinA (Xeomin) during the OLEX period.

Study Phase

Phase 3

Study Type


Primary Outcome

Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater)

Secondary Outcome

 Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by Subject Diary)




incobotulinumtoxinA (Xeomin)

Study Arms / Comparison Groups

 incobotulinumtoxinA (Xeomin)
Description:  incobotulinumtoxinA (Xeomin, also known as "NT 201" or "Botulinum toxin type A (150 kiloDalton), free from complexing proteins") powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to 50 Units per eye; Open-Label Extension Period: up to 5 injections, up to 50 Units per eye per injection session; Mode of administration: intramuscular injection


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

October 2006

Completion Date

July 2009

Primary Completion Date

April 2008

Eligibility Criteria

        Main Inclusion Criteria:

          -  Male or female pretreated outpatients between ages 18 and 80 years (inclusive)

          -  A clinical diagnosis of bilateral blepharospasm (BEB) characterized by spontaneous,
             spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi

          -  A need for injection of Botulinum toxin (defined by a Jankovic Rating Scale (JRS)
             severity subscore >= 2)

          -  On a stable dose of other medications (if any) used for focal dystonia treatment (e.g.
             anticholinergics and benzodiazepines) for at least 3 months prior to and expected
             throughout the Main Period

          -  Source documentation of the last two consecutive injection sessions with BOTOX® and a
             stable satisfactory therapeutic response directly prior to trial entry

          -  At least 10 weeks must have been passed between the last injection with BOTOX® for BEB
             and Baseline

        Main Exclusion Criteria:

          -  Atypical variant of BEB caused by inhibition of levator palpebrae muscle

          -  Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation
             and/or spinal cord stimulation)

          -  The previous two injections with BOTOX® with more than 50 Units per eye

          -  Hypersensitivity to human serum albumin, sucrose, or Botulinum toxin A

          -  Neuroleptic induced blepharospasm

          -  Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,
             or any other significant neuromuscular disease which might interfere with the trial

          -  Treatment with Botulinum toxins for any indication other than BEB within 4 months
             prior to Baseline and during the trial




18 Years - 80 Years

Accepts Healthy Volunteers



Joseph Jankovic, Prof., , 

Location Countries


Location Countries


Administrative Informations



Organization ID

MRZ 60201-0433

Responsible Party


Study Sponsor

Merz Pharmaceuticals GmbH

Study Sponsor

Joseph Jankovic, Prof., Study Chair, Houston, Texas

Verification Date

March 2013